Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

Tagraxofusp Leads to High Response Rates in Blastic Plasmacytoid Dendritic Cell Neoplasm

Ninety percent of patients with previously untreated blastic plasmacytoid dendritic cell neoplasm (BPDCN) responded to treatment with tagraxofusp, a CD123-targeted agent previously known as...

FDA Expands Ivosidenib’s Indication to Newly Diagnosed AML

On May 2, 2019, The U.S. Food and Drug Administration (FDA) approved an expanded indication for the IDH1 inhibitor ivosidenib to include the treatment...

Tibor Kovacsovics: CX-01 Associated With High Response Rates in Older Patients With AML

Tibor Kovacsovics, MD, discusses CX-01, a heparin derivative that induced high response rates in older patients newly diagnosed with acute myeloid leukemia.

Iman Abou Dalle: Leuprolide Improves Post-Chemotherapy Recovery in Patients With Leukemia

Iman Abou Dalle, MD, describes how blocking luteinizing hormone receptors with leuprolide can improve hematopoietic recovery in patients with leukemia who have undergone intensive...
On location

Exploring Safety and Efficacy of 5F9 and Azacitidine in AML and MDS

Watch our interview with David Sallman, MD.In initial results from a phase Ib trial presented at the 2019 American Society of Clinical Oncology annual...
David Sallman, MD

David Sallman: Early Results of 5F9 in AML and MDS

David Sallman, MD, discusses the initial results seen in a phase Ib trial of the anti-CD47 antibody 5F9 in patients with acute myeloid leukemia...
On location

CX-01 Combination Associated With High Response Rate in Older Patients With AML

Treatment with CX-01 and standard chemotherapy induced high response rates – including complete responses (CRs) – in older patients newly diagnosed with acute myeloid...

Hematologic Malignancies Drive In-Hospital Death Rates

In the past 17 years, the overall rate of in-hospital deaths among patients with hematologic malignancies has decreased by 30 percent, with a corresponding...

FDA’s ODAC Recommends Against Approval of Quizartinib for AML

In an 8-to-3 vote, the U.S. Food and Drug Administration’s (FDA’s) Oncologic Drug Advisory Committee (ODAC) decided against recommending approval of quizartinib for patients...

Japan Sets $306,000 Price for Tisagenlecleucel

The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel was approved for use in Japan in March 2019, and a government panel recently set the...

Current Issue

October 2019, Volume 5, Issue 12

This issue highlights the unintended consequences of fighting the nation’s opioid epidemic, considers the optimal frontline regimen for myeloma, and more.